Momentus Inc. Announces Fourth Quarter and Full Year 2022 Financial Results
Rood went on to say, “We see multiple opportunities for growth. We recently signed new and repeat commercial customers and are seeing increased interest in our services. We have begun to focus on growing our government business and are delighted that NASA contracted with us to fly two satellites on our next launch targeted for
The space economy continues to experience significant growth. The number of small satellites launched continues to grow to historic highs and new regulations put in place by the
Fourth Quarter 2022 Business Highlights:
- Applied lessons learned from the company’s inaugural mission with Vigoride 3 to the next generation Vigoride 5 Orbital Service Vehicle (OSV).
- Completed thermal vacuum testing of Vigoride 5, concluding its rigorous environmental testing campaign.
-
Integrated all customer satellites onto Vigoride 5, shipped Vigoride 5 to launch site, and completed all on-base preparation for launch including integration onto the
SpaceX Falcon 9 launch vehicle.
-
On
January 3, 2023 , subsequent to the close of the fourth quarter,Momentus launched Vigoride 5 to space onboard theSpaceX Transporter-6 mission fromCape Canaveral, Florida .
- Established communications with Vigoride 5 on its first orbital pass, deployed solar arrays, generated power nominally, commissioned the vehicle’s attitude determination system, and pressurized its propulsion system in anticipation of firing the Microwave Electrothermal Thruster.
-
Signed transportation contracts with new customer CONTEC, new customer
Australian Research Council Training Centre for CubeSats , Uncrewed Aerial Vehicles, and their Applications (CUAVA), repeat customer FOSSA Systems, and another repeat customer that wishes to remain anonymous.
-
Subsequent to the close of the fourth quarter, completed assembly, customer integration and ground-testing of Vigoride 6, the next spacecraft that the company plans to launch on the Transporter-7 mission, which
SpaceX is targeting forApril 2023 . Completed the Vigoride 6 Flight Readiness Review and shipped the vehicle to its launch site at Vandenberg Space Force Base inCalifornia where it has been integrated onto aSpaceX launch vehicle.
- Continued to implement the previously-announced cash-reduction plan and took steps to further extend Momentus’ cash runway.
-
Subsequent to the close of the quarter, reached agreement in principle to settle certain securities class action lawsuits. Under the settlement,
Momentus would pay$8.5 million to the plaintiffs, at least$4 million of which is expected to be funded by insurance proceeds.
-
Subsequent to the close of the quarter, issued
$10 million in stock and warrants to an institutional investor through a registered direct offering. The infusion of capital combined with the retirement of legacy challenges from the period beforeMomentus became a public company inAugust 2021 , enables the Company to focus on future growth.
Conference Call Information
About
Forward-Looking Statements
This press release contains certain statements which may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus’ control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: the ability of the Company to obtain licenses and government approvals for its missions, which are essential to its operations; the ability of the Company to effectively market and sell satellite transport services and planned in-orbit services; the ability of the Company to protect its intellectual property and trade secrets; the development of markets for satellite transport and in-orbit services; the ability of the Company to develop, test and validate its technology, including its water plasma propulsion technology; delays or impediments that the Company may face in the development, manufacture and deployment of next generation satellite transport systems; the ability of the Company to convert backlog or inbound inquiries into revenue; changes in applicable laws or regulations and extensive and evolving government regulations that impact operations and business, including export control license requirements; the ability to attract or maintain a qualified workforce with the required security clearances and requisite skills; product service or product or launch failures or delays that could lead customers to use competitors’ services; investigations, claims, disputes, enforcement actions, litigation and/or other regulatory or legal proceedings; the effects of the COVID-19 pandemic on the Company’s business; the Company’s ability to comply with the terms of its National Security Agreement and any related compliance measures instituted by the director who was approved by the CFIUS Monitoring Agencies (the “Security Director”); the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and/or other risks and uncertainties. These are only some of the factors that may affect the forward-looking statements contained in this press release. For a discussion identifying additional important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, see the company’s filings with the
Fiscal Year 2022 Financial Results
|
||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||
(in thousands, except share data) |
||||||||||||||||
|
Three Months Ended
|
|
Year Ended
|
|||||||||||||
|
2022 |
|
2021 |
|
2022 |
|
2021 |
|||||||||
Service revenue1 |
$ |
120 |
|
|
$ |
— |
|
|
$ |
299 |
|
|
$ |
330 |
|
|
Cost of (reversal of) revenue2 (exclusive of items shown separately below) |
|
— |
|
|
|
— |
|
|
|
26 |
|
|
|
(135 |
) |
|
Gross profit |
|
120 |
|
|
|
— |
|
|
|
273 |
|
|
|
465 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|||||||||
Research and development expenses |
|
10,283 |
|
|
|
11,574 |
|
|
|
41,721 |
|
|
|
51,321 |
|
|
Selling, general and administrative expenses |
|
10,929 |
|
|
|
13,103 |
|
|
|
49,827 |
|
|
|
48,905 |
|
|
Total operating expenses |
|
21,212 |
|
|
|
24,677 |
|
|
|
91,548 |
|
|
|
100,226 |
|
|
Loss from operations |
|
(21,092 |
) |
|
|
(24,677 |
) |
|
|
(91,275 |
) |
|
|
(99,761 |
) |
|
|
|
|
|
|
|
|
|
|||||||||
Other income (expense): |
|
|
|
|
|
|
|
|||||||||
Decrease (increase) in fair value of SAFE notes |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
209,291 |
|
|
Decrease (increase) in fair value of warrants |
|
1,803 |
|
|
|
27,505 |
|
|
|
5,185 |
|
|
|
37,330 |
|
|
Realized loss on disposal of asset |
|
(54 |
) |
|
|
(17 |
) |
|
|
(168 |
) |
|
|
(17 |
) |
|
Interest income |
|
489 |
|
|
|
— |
|
|
|
522 |
|
|
|
2 |
|
|
Interest expense |
|
(1,096 |
) |
|
|
(5,544 |
) |
|
|
(5,262 |
) |
|
|
(14,229 |
) |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(7,000 |
) |
|
Litigation settlement, net |
|
(4,500 |
) |
|
|
— |
|
|
|
(4,500 |
) |
|
|
— |
|
|
Other income (expense)3 |
|
10 |
|
|
|
5 |
|
|
|
54 |
|
|
|
(4,960 |
) |
|
Total other income |
|
(3,348 |
) |
|
|
21,949 |
|
|
|
(4,169 |
) |
|
|
220,417 |
|
|
(Loss) income before income taxes |
|
(24,440 |
) |
|
|
(2,728 |
) |
|
|
(95,444 |
) |
|
|
120,656 |
|
|
Income tax provision |
|
— |
|
|
|
1 |
|
|
|
— |
|
|
|
2 |
|
|
Net (loss) income |
$ |
(24,440 |
) |
|
$ |
(2,729 |
) |
|
$ |
(95,444 |
) |
|
$ |
120,654 |
|
|
Net (loss) income per share, basic |
$ |
(0.30 |
) |
|
$ |
(0.03 |
) |
|
$ |
(1.17 |
) |
|
$ |
1.85 |
|
|
Net (loss) income per share, fully diluted |
$ |
(0.30 |
) |
|
$ |
(0.03 |
) |
|
$ |
(1.17 |
) |
|
$ |
1.70 |
|
|
Weighted average shares outstanding, basic |
|
82,805,352 |
|
|
|
79,429,672 |
|
|
|
81,546,648 |
|
|
|
65,177,873 |
|
|
Weighted average shares outstanding, fully diluted |
|
82,805,352 |
|
|
|
79,429,672 |
|
|
|
81,546,648 |
|
|
|
70,918,777 |
|
1 |
- |
Prior year revenue recognized related to the cancellation of customer contracts, resulting in the forfeiture of customer deposits |
2
|
- |
The reduction of cost of revenue represents the reversal of a contingency recorded during the prior year for loss contracts related to free slots on future missions. During the prior year ended |
3 |
- |
Other expenses during the year ended |
|
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(in thousands) |
||||||||
|
|
|
|
|||||
|
|
|
|
|||||
ASSETS |
|
|
|
|||||
Current assets: |
|
|
|
|||||
Cash and cash equivalents |
$ |
61,094 |
|
|
$ |
160,036 |
|
|
Restricted cash, current |
|
1,007 |
|
|
|
197 |
|
|
Insurance receivable |
|
4,000 |
|
|
|
— |
|
|
Prepaids and other current assets |
|
10,173 |
|
|
|
9,431 |
|
|
Total current assets |
|
76,274 |
|
|
|
169,664 |
|
|
Property, machinery and equipment, net |
|
4,016 |
|
|
|
4,829 |
|
|
Intangible assets, net |
|
337 |
|
|
|
349 |
|
|
Operating right-of-use asset |
|
6,441 |
|
|
|
7,604 |
|
|
Deferred offering costs |
|
331 |
|
|
|
— |
|
|
Restricted cash, non-current |
|
312 |
|
|
|
314 |
|
|
Other non-current assets |
|
4,712 |
|
|
|
3,065 |
|
|
Total assets |
$ |
92,423 |
|
|
$ |
185,825 |
|
|
|
|
|
|
|||||
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|||||
Accounts payable |
|
2,239 |
|
|
|
1,911 |
|
|
Accrued expenses |
|
8,026 |
|
|
|
9,785 |
|
|
Loan payable, current |
|
11,627 |
|
|
|
20,907 |
|
|
Contract liabilities, current |
|
1,654 |
|
|
|
— |
|
|
Operating lease liability, current |
|
1,153 |
|
|
|
1,189 |
|
|
Stock repurchase liability |
|
10,000 |
|
|
|
— |
|
|
Litigation settlement contingency |
|
8,500 |
|
|
|
— |
|
|
Other current liabilities |
|
27 |
|
|
|
5,075 |
|
|
Total current liabilities |
|
43,226 |
|
|
|
38,867 |
|
|
Contract liabilities, non-current |
|
1,026 |
|
|
|
1,554 |
|
|
Loan Payable, non-current |
|
2,404 |
|
|
|
— |
|
|
Warrant liability |
|
564 |
|
|
|
5,749 |
|
|
Operating lease liability, non-current |
|
6,131 |
|
|
|
7,284 |
|
|
Other non-current liabilities |
|
465 |
|
|
|
483 |
|
|
Total non-current liabilities |
|
10,590 |
|
|
|
15,070 |
|
|
Total liabilities |
|
53,816 |
|
|
|
53,937 |
|
|
Commitment and Contingencies (Note 12) |
|
|
|
|||||
Shareholders’ equity: |
|
|
|
|||||
Common stock, |
|
1 |
|
|
|
1 |
|
|
Additional paid-in capital |
|
342,733 |
|
|
|
340,570 |
|
|
Accumulated deficit |
|
(304,127 |
) |
|
|
(208,683 |
) |
|
Total shareholders’ equity |
|
38,607 |
|
|
|
131,888 |
|
|
Total liabilities and shareholders’ equity |
$ |
92,423 |
|
|
$ |
185,825 |
|
|
||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
(in thousands) |
||||||||
|
Year Ended |
|||||||
|
2022 |
|
2021 |
|||||
Cash flows from operating activities: |
|
|
|
|||||
Net (loss) income |
$ |
(95,444 |
) |
|
$ |
120,654 |
|
|
Adjustments to reconcile net (loss) income to net cash used in operating activities: |
|
|
|
|||||
Depreciation and amortization |
|
1,090 |
|
|
|
1,092 |
|
|
Amortization of debt discount and issuance costs |
|
2,690 |
|
|
|
11,729 |
|
|
Amortization of right-of-use asset |
|
1,163 |
|
|
|
1,285 |
|
|
Decrease in fair value of warrants |
|
(5,185 |
) |
|
|
(37,330 |
) |
|
Decrease in fair value of SAFE notes |
|
— |
|
|
|
(209,291 |
) |
|
Impairment of prepaid launch costs |
|
— |
|
|
|
9,450 |
|
|
Litigation settlement, net |
|
4,500 |
|
|
|
— |
|
|
Loss on disposal of fixed and intangible assets |
|
168 |
|
|
|
17 |
|
|
Stock-based compensation expense |
|
11,580 |
|
|
|
18,452 |
|
|
Changes in operating assets and liabilities: |
|
|
|
|||||
Prepaids and other current assets |
|
(2,206 |
) |
|
|
(14,373 |
) |
|
Other non-current assets |
|
(147 |
) |
|
|
(325 |
) |
|
Accounts payable |
|
373 |
|
|
|
1,562 |
|
|
Accrued expenses |
|
(1,540 |
) |
|
|
7,042 |
|
|
Accrued interest |
|
131 |
|
|
|
— |
|
|
Other current liabilities |
|
(5,020 |
) |
|
|
4,810 |
|
|
Contract liabilities |
|
1,126 |
|
|
|
(1,071 |
) |
|
Lease liability |
|
(1,189 |
) |
|
|
(426 |
) |
|
Other non-current liabilities |
|
23 |
|
|
|
11 |
|
|
Net cash used in operating activities |
|
(87,887 |
) |
|
|
(86,712 |
) |
|
|
|
|
|
|||||
Cash flows from investing activities: |
|
|
|
|||||
Purchases of property, machinery and equipment |
|
(583 |
) |
|
|
(2,972 |
) |
|
Proceeds from sale of property, machinery and equipment |
|
34 |
|
|
|
— |
|
|
Purchases of intangible assets |
|
(184 |
) |
|
|
(118 |
) |
|
Net cash used in investing activities |
|
(733 |
) |
|
|
(3,090 |
) |
|
|
|
|
|
|||||
Cash flows from financing activities: |
|
|
|
|||||
Proceeds from issuance of SAFE notes |
|
— |
|
|
|
30,853 |
|
|
Proceeds from issuance of loan payable |
|
— |
|
|
|
25,000 |
|
|
Proceeds from exercise of stock options |
|
574 |
|
|
|
336 |
|
|
Proceeds from employee stock purchase plan |
|
271 |
|
|
|
— |
|
|
Repurchase of Section 16 Officer shares for tax coverage exchange |
|
(331 |
) |
|
|
(151 |
) |
|
Payment of loan payable |
|
(9,697 |
) |
|
|
(1,500 |
) |
|
Payment of debt issuance costs |
|
— |
|
|
|
(144 |
) |
|
Payment of warrant issuance costs |
|
— |
|
|
|
(31 |
) |
|
Payment of deferred offering costs |
|
(331 |
) |
|
|
— |
|
|
Payment for repurchase of common shares |
|
— |
|
|
|
(40,000 |
) |
|
Proceeds from issuance of common shares in PIPE |
|
— |
|
|
|
110,000 |
|
|
Payments of issuances costs related to PIPE |
|
— |
|
|
|
(4,416 |
) |
|
Proceeds from issuance of common stock upon Business Combination |
|
— |
|
|
|
128,167 |
|
|
Payments for issuance costs related to Business Combination |
|
— |
|
|
|
(21,285 |
) |
|
Net cash (used in) provided by financing activities |
|
(9,514 |
) |
|
|
226,829 |
|
|
|
|
|
|
|||||
(Decrease) Increase in cash, cash equivalents and restricted cash |
|
(98,134 |
) |
|
|
137,027 |
|
|
Cash, cash equivalents and restricted cash, beginning of period |
|
160,547 |
|
|
|
23,520 |
|
|
Cash, cash equivalents and restricted cash, end of period |
$ |
62,413 |
|
|
$ |
160,547 |
|
|
|
|
|
|
|||||
Supplemental disclosure of non-cash investing and financing activities |
|
|
|
|||||
Issuance of common stock related to conversion of SAFE notes |
$ |
— |
|
|
$ |
136,001 |
|
|
Issuance of common stock related to exercise of warrant liabilities |
$ |
— |
|
|
$ |
6,999 |
|
|
Reclassification of deferred offering costs |
$ |
— |
|
|
$ |
2,610 |
|
|
Assumption of merger warrants liability |
$ |
— |
|
|
$ |
31,225 |
|
|
Operating lease right-of-use assets in exchange for lease obligations |
$ |
— |
|
|
$ |
8,501 |
|
|
Stock repurchase liability fair value |
$ |
10,000 |
|
|
$ |
— |
|
|
|
|
|
|
|||||
Supplemental disclosure of cash flow information |
|
|
|
|||||
Cash paid for income taxes |
$ |
— |
|
|
$ |
1 |
|
|
Cash paid for interest |
$ |
2,440 |
|
|
$ |
2,500 |
|
Reclassifications
Certain reclassifications have been made to the prior year’s financial statements to conform to the current year’s presentation. None of the reclassifications have changed the total assets, liabilities, shareholders’ deficit, income, expenses or net losses previously reported.
Use of Non-GAAP Financial Measures (unaudited)
This press release references certain non-GAAP financial measures, including adjusted EBITDA, non-GAAP selling, general, and administrative expense and non-GAAP research and development expense. The Company defines adjusted EBITDA as earnings before interest expense, taxes, depreciation and amortization, stock-based compensation, and certain other items the Company believes are not indicative of its core operating performance. The Company defines non-GAAP selling, general, and administrative expenses and research and development expenses as those respective GAAP amounts, excluding stock-based compensation and non-recurring items not indicative of core operating performance None of these non-GAAP financial measures is a substitute for or superior to measures of financial performance prepared in accordance with generally accepted accounting principles in
The Company believes that presenting these non-GAAP financial measures provides useful supplemental information to investors about the Company that is helpful in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational-decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies.
Full year adjusted EBITDA
A reconciliation of adjusted EBITDA to net loss for the years ended
|
Year Ended |
||||||
(in thousands) |
2022 |
|
2021 |
||||
Net Income (Loss) |
$ |
(95,444 |
) |
|
$ |
120,654 |
|
Income tax expense |
|
— |
|
|
|
2 |
|
Interest income |
|
(522 |
) |
|
|
(2 |
) |
Interest expense |
|
5,262 |
|
|
|
14,229 |
|
Depreciation & amortization |
|
1,090 |
|
|
|
1,092 |
|
EBITDA |
|
(89,614 |
) |
|
|
135,975 |
|
(Decrease) increase in fair value of SAFE notes |
|
— |
|
|
|
(209,291 |
) |
(Decrease) increase in fair value of warrants |
|
(5,185 |
) |
|
|
(37,330 |
) |
Realized loss on disposal of assets |
|
168 |
|
|
|
17 |
|
|
|
— |
|
|
|
7,000 |
|
Litigation settlement, net |
|
4,500 |
|
|
|
— |
|
Transaction costs allocated to warrant liability |
|
— |
|
|
|
4,780 |
|
Investment banking fees related to SAFE financing |
|
— |
|
|
|
175 |
|
Prepaid launch deposit impairment |
|
— |
|
|
|
9,450 |
|
|
|
1,740 |
|
|
|
10,038 |
|
Reduction in |
|
— |
|
|
|
(2,551 |
) |
Class action litigation legal expenses |
|
2,659 |
|
|
|
852 |
|
Other non-recurring litigation legal expense |
|
1,736 |
|
|
|
— |
|
|
|
2,268 |
|
|
|
1,073 |
|
|
|
2,530 |
|
|
|
1,835 |
|
Severance and other non-recurring expenses |
|
421 |
|
|
|
136 |
|
Stock-based compensation |
|
11,580 |
|
|
|
18,452 |
|
Adjusted EBITDA |
$ |
(67,197 |
) |
|
$ |
(59,389 |
) |
A reconciliation of selling, general, and administrative expenses to non-GAAP selling, general, and administrative expenses for the years ended
|
Year Ended |
||||||
(in thousands) |
2022 |
|
2021 |
||||
Selling, general, and administrative expenses |
$ |
49,827 |
|
$ |
48,905 |
|
|
Stock-based compensation |
|
9,446 |
|
|
|
16,111 |
|
|
|
1,740 |
|
|
|
10,038 |
|
Reduction in |
|
— |
|
|
|
(2,551 |
) |
Class action litigation legal expenses |
|
2,659 |
|
|
|
852 |
|
Other non-recurring litigation legal expense |
|
1,736 |
|
|
|
— |
|
|
|
2,268 |
|
|
|
1,073 |
|
|
|
2,530 |
|
|
|
1,835 |
|
Severance and other non-recurring expenses |
|
155 |
|
|
|
63 |
|
Non-GAAP selling, general, administration expenses |
$ |
29,293 |
|
|
$ |
21,484 |
|
A reconciliation of research and development expenses to non-GAAP research and development expenses for the years ended
|
Year Ended |
||||||
(in thousands) |
2022 |
|
2021 |
||||
Research and development expenses |
$ |
41,721 |
|
$ |
51,321 |
||
Prepaid launch deposit impairment |
|
— |
|
|
|
9,450 |
|
Stock-based compensation |
|
2,134 |
|
|
|
2,341 |
|
Severance and other non-recurring expenses |
|
388 |
|
|
|
74 |
|
|
$ |
39,199 |
|
|
$ |
39,456 |
|
Quarterly adjusted EBITDA
A reconciliation of adjusted EBITDA to net loss for the three months ended
|
Three Months Ended |
||||||||||
(in thousands) |
|
|
|
|
|
||||||
Net Income (Loss) |
$ |
(24,440 |
) |
|
$ |
(2,729 |
) |
|
$ |
(21,298 |
) |
Income tax expense |
|
— |
|
|
|
1 |
|
|
|
— |
|
Interest income |
|
(489 |
) |
|
|
— |
|
|
|
(28 |
) |
Interest expense |
|
1,096 |
|
|
|
5,544 |
|
|
|
1,261 |
|
Depreciation & amortization |
|
259 |
|
|
|
324 |
|
|
|
253 |
|
EBITDA |
|
(23,574 |
) |
|
|
3,140 |
|
|
|
(19,812 |
) |
(Decrease) increase in fair value of warrants |
|
(1,803 |
) |
|
|
(27,505 |
) |
|
|
(1,579 |
) |
Realized loss on disposal of assets |
|
54 |
|
|
|
17 |
|
|
|
45 |
|
Litigation settlement, net |
|
4,500 |
|
|
|
— |
|
|
|
— |
|
|
|
161 |
|
|
|
464 |
|
|
|
279 |
|
Reduction in |
|
— |
|
|
|
(2,551 |
) |
|
|
— |
|
Class action litigation legal expenses |
|
755 |
|
|
|
797 |
|
|
|
621 |
|
Other non-recurring litigation legal expense |
|
1,004 |
|
|
|
— |
|
|
|
447 |
|
|
|
76 |
|
|
|
1,073 |
|
|
|
20 |
|
|
|
233 |
|
|
|
905 |
|
|
|
487 |
|
Severance and other non-recurring expenses1 |
|
— |
|
|
|
(13 |
) |
|
|
90 |
|
Stock-based compensation |
|
3,044 |
|
|
|
7,265 |
|
|
|
3,289 |
|
Adjusted EBITDA |
$ |
(15,550 |
) |
|
$ |
(16,408 |
) |
|
$ |
(16,113 |
) |
1 |
- |
Loss contingencies for certain severance agreements were reversed when the Company determined they would not be signed and paid |
A reconciliation of selling, general, and administrative expenses to non-GAAP selling, general, and administrative expenses for the three months ended
|
Three Months Ended |
||||||||||
(in thousands) |
|
|
|
|
|
||||||
Selling, general, and administrative expenses |
$ |
10,929 |
|
$ |
13,103 |
|
|
$ |
11,184 |
||
Stock-based compensation |
|
2,534 |
|
|
|
5,109 |
|
|
|
2,552 |
|
|
|
161 |
|
|
|
464 |
|
|
|
279 |
|
Reduction in |
|
— |
|
|
|
(2,551 |
) |
|
|
— |
|
Class action litigation legal expenses |
|
755 |
|
|
|
797 |
|
|
|
621 |
|
Other non-recurring litigation legal expense |
|
1,004 |
|
|
|
— |
|
|
|
447 |
|
|
|
76 |
|
|
|
1,073 |
|
|
|
20 |
|
|
|
233 |
|
|
|
905 |
|
|
|
487 |
|
Severance and other non-recurring expenses1 |
|
— |
|
|
|
(13 |
) |
|
|
52 |
|
Non-GAAP selling, general, administration expenses |
$ |
6,166 |
|
|
$ |
7,318 |
|
|
$ |
6,726 |
|
1 |
- |
Loss contingencies for certain severance agreements were reversed when the Company determined they would not be signed and paid |
A reconciliation of research and development expenses to non-GAAP research and development expenses for the three months ended
|
Three Months Ended |
||||||||||
(in thousands) |
|
|
|
|
|
||||||
Research and development expenses |
$ |
10,283 |
|
$ |
11,574 |
|
$ |
10,571 |
|||
Stock-based compensation |
|
510 |
|
|
|
2,156 |
|
|
|
737 |
|
Severance and non-recurring expenses |
|
— |
|
|
|
— |
|
|
|
38 |
|
|
$ |
9,773 |
|
|
$ |
9,418 |
|
|
$ |
9,796 |
|
1 |
- |
Loss contingencies for certain severance agreements were reversed when the Company determined they would not be signed and paid |
_______________
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307006003/en/
For media inquiries:
press@momentus.space
For investor relations inquiries:
investors@momentus.space
Source: